VistaGen Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VistaGen Therapeutics, Inc. on January 10, 2013, covering events occurring on January 6, 2013. The company is a Nevada corporation headquartered in South San Francisco, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements.
Material Changes
Effective January 6, 2013, Gregory A. Bonfiglio resigned from his position as a Director and member of the Audit Committee. Mr. Bonfiglio had served on the Board of Directors since 2007. His departure was to assume full-time responsibilities as the managing principal of a newly formed, privately-held hedge fund.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the notification of the director's resignation.
Key Facts for Investor Verification
- Gregory A. Bonfiglio resigned from the Board of Directors and Audit Committee effective January 6, 2013.
- The resignation was voluntary to pursue a new role at a privately-held hedge fund.
- The company's CEO, Shawn K. Singh, signed the report on January 10, 2013.
- No financial data or operational updates were included in this specific filing.